33rd week of 2009 patent applcation highlights part 33 |
Patent application number | Title | Published |
20090202523 | ANTIBODIES AGAINST A PEPTIDE EPITOPE OF APOLIPOROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 2009-08-13 |
20090202524 | PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS - The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a PAI-1-associated ocular disorder in a subject in need, comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 activity or expression. | 2009-08-13 |
20090202525 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE - The present invention relates to compounds of Formula (1), | 2009-08-13 |
20090202526 | Agonist anti-trkc antibodies and methods using same - The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy. | 2009-08-13 |
20090202527 | TREATMENT FOR MULTIPLE SCLEROSIS - Methods of treating multiple sclerosis and other disorders are disclosed. | 2009-08-13 |
20090202528 | Surface-Located Streptococcus Pneumoniae Polypeptides - The present invention relates to cell-surface-located polypeptides of | 2009-08-13 |
20090202529 | Use of egfr inhibitors to prevent or treat obesity - Methods of treating or preventing obesity or obesity related disorders in a subject are provided, comprising administering to the subject a treatment effective in reducing one or more activities of an epidermal growth factor receptor (EGFR) in the subject. Methods of screening for compositions that can modulate one or more EGFR activities are also provided. | 2009-08-13 |
20090202530 | Identification of Tumor-Associated Antigens for Diagnosis and Therapy - The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases. | 2009-08-13 |
20090202531 | USES OF ANTI-CD40 ANTIBODIES - Methods for treating a human patient for an inflammatory or autoimmune disease that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with an inflammatory or autoimmune disease that is treatable with an anti-CD40 antibody and which is non-responsive or refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having an inflammatory or autoimmune disease that is non-responsive or refractory to treatment with rituximab (Rituxan®), are also provided. The methods of the present invention find use in treatment of inflammatory diseases and autoimmune diseases that are associated with CD40-expressing cells. These methods are particularly advantageous with respect to inflammatory diseases and autoimmune diseases that are associated with cells expressing both CD40 and CD20, as the methods enable the treatment of patients having an inflammatory or autoimmune disease that is non-responsive or refractory to therapy with other therapeutic agents such as anti-CD20 antibodies. | 2009-08-13 |
20090202532 | High Functional Bispecific Antibody - [Problem]The purpose of the present invention is to provide a bispecific antibody that is structurally stable, and can show alone a sufficient effect without the co-administration of activated lymphocyte (T-LAK).
| 2009-08-13 |
20090202533 | TREATMENT AND PROPHYLAXIS OF TH2 MEDIATED DISORDERS - The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11. | 2009-08-13 |
20090202534 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES - Disclosed is a newly identified CD28 family member that functions as lymphocyte inhibitory receptor termed pG6b, which is expressed on T cells. Methods and compositions for modulating pG6b-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic, and research purposes are also disclosed. | 2009-08-13 |
20090202535 | Method for neutralizing effects of sPLA2 - A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which
| 2009-08-13 |
20090202536 | ANTIBODY-DRUG CONJUGATES AND METHODS - The present invention relates to antibody-drug conjugate compounds of Formula I: | 2009-08-13 |
20090202537 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer (preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma), autoimmune disease, inflammatory disease or IgE-mediated allergic disorder. The present invention also encompasses the use of a humanized FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention with a vaccine composition. | 2009-08-13 |
20090202538 | F11 RECEPTOR (F11R) ANTAGONISTS AS THERAPEUTIC AGENTS - The present invention provides a cell adhesion molecule (CAM), designated F11 receptor (F11R) and its use to inhibit platelet aggregation and platelet adhesion for the treatment and prevention of cardiovascular disorders. Cloned F11R cDNA and full length F11R cDNA and amino acid sequences are provided. F11R-antagonists and methods for the prevention and treatment of thrombosis, atherosclerosis, heart attacks, stroke and other clinical disorders involving thrombus formation are also provided. There are at least two kinds of antagonists that may be employed together. Peptides derived from the extracellular domain of F11R and small molecules and peptidomimetics based on the structure of these peptides, as well as inhibitory antibodies and functional fragments thereof, are shown to inhibit human platelet aggregation and platelet adhesion to endothelial cells, and therefore, inhibit the formation of atherosclerotic plaques. | 2009-08-13 |
20090202539 | METHOD FOR TREATING CANCER USING ANTI-WNT2 MONOCLONAL ANTIBODIES AND siRNA - This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such as a Frizzled receptor. | 2009-08-13 |
20090202540 | SUBSTITUTED OXAZAPHOSPHORINES - The present invention relates to new oxazaphosphorine alkylating agents and/or immuno-suppressive agents, pharmaceutical compositions thereof, and methods of use thereof. | 2009-08-13 |
20090202541 | COMBINATION COMPRISING N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL)-4-(3-P- YRIDYL)-2PYRIMIDINE-AMINE AND A CHEMOTHERAPEUTIC AGENT - A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute or chronic transplant rejection; a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease. | 2009-08-13 |
20090202542 | Rage protein derivatives - The present invention is drawn to fusion proteins comprising a Receptor for Advanced Glycation Endproducts (RAGE) and an immunoglobulin element. The invention also encompasses methods of treating a condition characterized by activation of an inflammatory cytokine cascade comprising administering such fusion proteins. The invention is also drawn to nucleic acids encoding the fusion proteins, as well as vectors and cells comprising such nucleic acids. | 2009-08-13 |
20090202543 | GENE AND POLYPEPTIDE RELATING TO BREAST CANCER - The present application provides novel human gene B7330N whose expression is markedly elevated in breast cancers. The gene and polypeptide encoded by the gene can be used, for example, in the diagnosis of breast cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of breast cancer. | 2009-08-13 |
20090202544 | Methods of Treating Diseases by Targeting Silt3 - This invention provides a method of treating a subject afflicted with a disease, comprising withdrawing blood from the subject, treating the withdrawn blood so as to remove sILT3 from the blood, and returning the treated blood to the subject, thereby treating the subject afflicted with the disease. This invention also provides the above method, further comprising administering an anti-ILT3 antibody to the subject. The invention also provides a method of treating a subject afflicted with a disease, comprising administering to the subject an anti-ILT3 antibody, thereby treating the subject. In one embodiment, the disease is chronic viral disease. In another embodiment, the disease is cancer. | 2009-08-13 |
20090202545 | MELANOMA BIOMARKER AND METHODS OF USES - The present invention relates to the use of TROY, also called tumor necrosis factor receptor superfamily, member 19 (TNFRSF 19) also called toxicity and JNK inducer (TAJ), in diagnosis and therapy of non-epithelial cancers, such as melanoma. Accordingly, the invention provides in vitro and in vivo diagnostic and/or prognostic methods for cancers, other than epithelial cancers, preferably melanoma, comprising analyzing TROY expression in a biological sample from an individual or in an individual, wherein expression of TROY in non-epithelial cells, such as in melanocytes, in indicative the biological sample or the individual containing malignant cells, such as malignant melanoma cells. The invention also provides therapeutic use of TROY targeting molecules, such as TROY antibodies or TROY targeting RNA interfering agents for treatment of cancer wherein the cancer cells express TROY. | 2009-08-13 |
20090202546 | COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF - A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed. | 2009-08-13 |
20090202547 | ANTIBODIES THAT BLOCK RECEPTOR PROTEIN TYROSINE KINASE ACTIVATION, METHODS OF SCREENING FOR AND USES THEREOF - Molecules comprising the antigen-binding portion of antibodies that block constitutive and/or ligand-dependent activation of a receptor protein tyrosine kinase, such as fibroblast growth factor receptor 3 (FGFR3), are found through screening methods, where a soluble dimeric form of a receptor protein tyrosine kinase is used as target for screening a library of antibody fragments displayed on the surface of bacteriophage. The molecules of the present invention which block constitutive activation can be administered to treat or inhibit skeletal dysplasia, craniosynostosis disorders, cell proliferative diseases or disorders, or tumor progression associated with the constitutive activation of a receptor protein tyrosine kinase. | 2009-08-13 |
20090202548 | ANTIBODIES AND RELATED MOLECULES THAT BIND TO PSCA PROTEINS - Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization. | 2009-08-13 |
20090202549 | Anti-IL-12 Antibodies, Epitopes, Compositions, Methods and Uses - An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 2009-08-13 |
20090202550 | MONOCLONAL ANTIBODIES AND IMMUNODETECTION ASSAY SPECIFIC FOR THE CHEMOTACTIC EPITOPE OF THE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR - The present invention describes monoclonal antibodies specific for the chemotactic epitope of the uPAR. In particular, the invention comprises monoclonal antibodies against uPAR fragments specifically recognizing in whole or in part the chemotactic sequence of uPAR connecting domain 1 to domain 2. | 2009-08-13 |
20090202551 | IMMUNOMODULATION BY ALTERING SPHINGOSINE 1-PHOSPHATE LYASE (SPL) ACTIVITY - Compositions and methods for modulating immune function are provided based on the unexpected discovery that inhibition of sphingosine-1-phosphate lyase (SPL) activity confers useful immunosuppressive effects, for example to modulate immune function in treatment or prevention of inflammation, transplant graft rejection, autoimmune disease, allergy, or other conditions, including therapeutic alteration of immune system cell survival and/or proliferation. Altering SPL activity by direct or indirect pharmacological intervention, or alternatively by molecular genetic methods to alter SPL expression levels, are also contemplated. | 2009-08-13 |
20090202552 | GENE EXPRESSED IN PROSTATE CANCER AND METHODS OF USE - A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specifically bind NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP. Assays are disclosed for the detection prostate cancer. Pharmaceutical compositions including an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer. | 2009-08-13 |
20090202553 | Antibodies against anthrax protective antigen - A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided. Methods for diagnosis and methods to determine anthrax contamination are also described. | 2009-08-13 |
20090202554 | METHOD OF MODULATION OF INTERACTION BETWEEN RECEPTOR AND LIGAND - The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The invention features a binding site of said functional cell-surface receptor on the receptor ligand and discloses a series of amino acid sequences, which are part of the structure of said binding site and/or involved in the interaction between the receptor and the ligand. Moreover, the present invention features methods for molecular design and screening of a candidate compound capable of modulating the interaction between the functional cell-surface receptor and receptor ligand through the described binding site, and provides a screening assay for identification of such a compound. The invention further describes an antibody capable of binding to the above binding site and/or to an epitope comprising an amino acid sequence essential for executing the receptor ligand interaction through said binding site. The invention also concerns a variety of uses of the disclosed methods, peptide sequences and antibodies. The invention in preferred embodiments concerns the binding site of the fibroblast growth factor receptor (FGFR) on FGFR ligands, compounds capable of modulating the receptor ligand interaction through sa d binding site, and antibody capable of recognition of said binding site. | 2009-08-13 |
20090202555 | ANTIBODIES AGAINST A PEPTIDE EPITOPE OF APOLIPOROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 2009-08-13 |
20090202556 | ANTI-CLAUDIN-4 ANTIBODY - An object of the present invention is to provide a monoclonal antibody which is useful as a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by Claudin-4 (hereinafter referred to as “CLDN4”) gene or a polypeptide encoded by a Claudin-3 (hereinafter referred to as “CLDN3”) gene, or a method for using the same. Accordingly, the present invention provides a monoclonal antibody or an antibody fragment thereof, which specifically recognizes three-dimensional structure of an extracellular region of CLDN4 and binds to the extracellular region; a monoclonal antibody or an antibody fragment thereof, which specifically recognizes three-dimensional structure of both of extracellular regions of CLDN3 and CLDN4 and binds to the extracellular regions; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtained by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by CLDN4 gene and/or CLDN3 gene using the antibody or the antibody fragment. | 2009-08-13 |
20090202557 | Compositions and methods for crystallizing antibody fragments - The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of the antibody 125-2H or a human Fab fragment of the antibody ABT-325, which bind to IL-18, are provided as well as a co-crystal of a murine Fab fragment bound to IL-18. ABT-325 and 125-2H differ significantly in combining site character and architecture, thus explaining their ability to bind IL-18 simultaneously at distinct epitopes. | 2009-08-13 |
20090202558 | TNFalpha-NEUTRALIZING ANTIBODIES - The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications. | 2009-08-13 |
20090202559 | Anti-Mesothelin Antibodies - This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments. | 2009-08-13 |
20090202560 | Method for diagnosing efficacy of xenotypic antibody therapy - The invention concerns methods and compositions for intiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen. | 2009-08-13 |
20090202561 | NOVEL RAAG10 CELL SURFACE TARGET AND A FAMILY OF ANTIBODIES RECOGNIZING THAT TARGET - The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10. | 2009-08-13 |
20090202562 | ANTI-GFRALPHA3 ANTIBODIES - Antibodies and antibody fragments that bind to the receptor GFRalpha3 and inhibit formation of a Neublastin-GFRalpha3-Ret ternary complex are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit phosphorylation of Ret in a cell and treat disorders and in a subject. | 2009-08-13 |
20090202563 | C20ORF23 as modifier of the IGFR pathway and methods of use - Human C20ORF23 genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of C20ORF23 are provided. | 2009-08-13 |
20090202564 | METHODS OF ISOLATING STEM CELLS - The present inventors discovered for the first time that labeling cell nuclei makes it possible to efficiently isolate stem cells. Namely, it was elucidated that stem cells with labeled nuclei remained labeled even after cell division, and showed self-renewing and long-living abilities characteristic of stem cells. Efficient isolation of stem cells is possible, for instance, by labeling the nuclear of each cell in a heterogeneous cellular group followed by selecting those cells that maintain a labeled state even after cell division. The present invention provides methods for enabling visualization of stem cells of animal tissues in a living state by labeling using the essential functions of the stem cells, and methods for simply and easily isolating the stem cells in a fresh state without using at all genetic manipulation or artificial markers. | 2009-08-13 |
20090202565 | TORC POLYNUCLEOTIDES AND POLYPEPTIDES AND METHOD OF USE - The present invention relates to a broad range of methods that utilize a transducer of regulated CREB (TORC)-related polynucleotide, polypeptide, or TORC-specific antibody. In addition the invention relates to TORC-related polynucleotide, polypeptide, or TORC-specific antibody compositions, including variants of TORC wild-type sequences. Exemplary methods include a method of stimulating a TORC related process in a cell as well as a method of inhibiting a TORC-related process in a cell, and a method of inhibiting TORC-related processes in a cell. The invention additionally discloses therapeutic methods of substantially inhibiting the development of, treating, or ameliorating a disease or pathological condition in a subject related to an abnormal level of a TORC-activated process in a cell that includes administering one or more therapeutically effective doses to the subject of either a substance that modulates accumulation of a TORC polypeptide in a subcellular region of the cell, or of a substance that inhibits expression of a TORC polypeptide in the cell. In an additional aspect a method of identifying an agent that modulates the activity of a TORC-related process in a cell is disclosed. In still a further aspect the invention relates to a method of detecting the presence or quantifying the amount of a TORC polypeptide in a sample. In a further aspect, a method is disclosed of determining whether the amount of a TORC polypeptide in a sample differs from the amount of the TORC polypeptide in a reference. An additional aspect relates to a method of contributing to the diagnosis or prognosis of, or to developing a therapeutic strategy for, a disease or pathology in a first subject, wherein the subcellular localization of a TORC polypeptide in the pathology is known to differ from the subcellular localization of the TORC polypeptide in a nonpathological state. | 2009-08-13 |
20090202566 | Use of the ENDO-180 gene and polypeptide for diagnosis and treatment - This application is directed to a process of identifying a compound capable of modulating activity of a human ENDO180 receptor that comprises the steps of measuring the binding of the ENDO180 receptor to an interactor with which the ENDO180 receptor interacts specifically in vivo, in the absence or presence of a compound, and determining whether the binding of the ENDO180 receptor to the interactor is affected by the compound. This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular fibrosis. This application also relates to the use of ENDO180 modulators in treatment of disease. | 2009-08-13 |
20090202567 | OLIGONUCLEOTIDES OR THEIR FUNCTIONAL HOMOLOGUES, A COMPOSITION COMPRISING THE SAME AND A METHOD OF TREATING B CELL NEOPLASM - The invention provides nine oligonucleotides with sequences of SEQ ID NO: 1-9 or their functional homologues or a composition comprising the same and a method for treating B cell neoplasm by using the oligonucleotides or their functional homologues or the composition comprising the oligonucleotides. The oligonucleotides induce the apoptosis of B cell neoplastic cells, up-regulate CD40 on B cell neoplastic cells and stimulate the production of IL-10 from B cell neoplastic cells. | 2009-08-13 |
20090202568 | Binding members for interleukin-4 receptor alpha (IL-4Ra)-173 - Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4Rα), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4Rα, IL-4 and/or IL-13, examples of which are asthma and COPD. | 2009-08-13 |
20090202569 | Prophylactic/Therapeutic Agent for Cancer - The present invention provides a preventative/therapeutic agent for cancer capable of selectively and effectively killing cancer cells. A medicament of the present invention prepared by combining at least one selected from a substance that inhibits the activity of an enzyme belonging to the acyl-CoA synthase family and a substance that inhibits expression of a gene for an enzyme belonging to the acyl-CoA synthase family, with at least one selected from a substance that inhibits the activity of fatty acid synthase and a substance that inhibits expression of a fatty acid synthase gene and the like can be used as a preventative/therapeutic agent for cancer capable of selectively and effectively killing cancer cells. | 2009-08-13 |
20090202570 | PM-2 ANTIBODIES, FUNCTIONAL FRAGMENTS AND METHODS FOR TREATING METASTASIS - The invention provides PM-2 antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One method includes treating metastasis of a neoplasia, tumor or cancer in a subject in need of treatment by administering to the subject an amount of a PM-2 antibody or functional fragment thereof effective to treat metastasis of the neoplasia, tumor or cancer in the subject. | 2009-08-13 |
20090202571 | Bioreductively-activated prodrugs - A compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: —Ar is a substituted heteroaryl group bearing at least one nitro or azido group or is a benzoquinone, naphthoquinone or fused heterocyloquinone; -R1 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; -R2 is a glycoside, OH, optionally substituted alkyl, optionally substituted alkoxy, C | 2009-08-13 |
20090202572 | COMPOSITIONS AND METHODS FOR MODULATING BONE MASS - The instant invention relates to compositions and methods for treating or preventing bone diseases. In certain aspects, the invention provides compositions comprising a β-adrenergic antagonist or agonist associated to a bone-targeted molecule, as well as methods of modulating bone mass and/or growth in a mammal by administering a composition of the present invention. In other aspects, the invention provides methods of modulating bone mass and/or growth in a mammal by administering a composition comprising a β2-selective antagonist or agonist. | 2009-08-13 |
20090202573 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES - The present invention provides polymeric conjugates containing positively charged moieties. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 2009-08-13 |
20090202574 | METHODS OF IMMUNE OR HAEMATOLOGICAL ENHANCEMENT, INHIBITING TUMOUR FORMATION OR GROWTH, AND TREATING OR PREVENTING CANCER - The present invention relates to administration of metal ion-saturated lactoferrin, preferably bovine lactoferrin, preferably iron-saturated bovine lactoferrin, or a metal ion-saturated functional variant or fragment thereof to inhibit tumour formation or growth, maintain or improve one or both of the white blood cell count and red blood cell count, stimulate the immune system and treat or prevent cancer. The methods and medicinal uses of the invention may be carried out by employing dietary (as foods or food supplements), nutraceutical or pharmaceutical compositions. Compositions useful in the methods of the invention are also provided. | 2009-08-13 |
20090202575 | IMMUNOSTIMULATORY NUCLEIC ACID MOLECULES - Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. | 2009-08-13 |
20090202576 | PEPTIDE VACCINES FOR LUNG CANCERS EXPRESSING TTK, URLC10 OR KOC1 POLYPEPTIDES - The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors comprising these peptides. The peptides of the present invention can also be used as vaccines. | 2009-08-13 |
20090202577 | CASB618 Polynucleotides and Polypeptides and Their Use - CASB618 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB618 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly ovarian and colon cancers, autoimmune diseases, and related conditions. | 2009-08-13 |
20090202578 | SURFACE PROTEINS FROM COAGULASE-NEGATIVE STAPHYLOCOCCI AND STAPHYLOCOCCUS AUREUS THAT GENERATE CROSS-REACTIVE MONOCLONAL AND POLYCLONAL ANTIBODIES - Surface proteins are provided which generate polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive | 2009-08-13 |
20090202579 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING MALARIA (2) - The present invention provides compositions and methods useful in the treatment or prevention of a condition caused by or associated with infection by | 2009-08-13 |
20090202580 | METHOD FOR THE PREPARATION OF SPECIFIC ANTIBODIES AGAINST SACCHARIDIC ANTIGENS - The present invention relates to new compounds useful for the stimulation of the production of antibodies. Said compounds comprises a saccharidic tumor antigen and a polymeric scaffold. The present invention also encompasses conjugated compounds useful in ELISA assay for the selection of antibodies against saccharidic antigens. | 2009-08-13 |
20090202581 | Cosmetic formulation - The present invention provides an improved skin care formulation for enhancing the overall quality of the skin and treating aging skin comprising cassia angustilfolia seed polysaccharide, dipeptide-4, glutamylamidoethyl indole, and kluyveromyces extract, in a cosmetically/dermatologically acceptable medium. The formulation improves skin quality by moisturizing and softening the skin, while protecting and repairing damaged sensitive skin, activating skin restructuration and stimulating collagen and keratin synthesis. Additionally, the formulation protects the skin from stress and oxidation, and reduces protein carbonylation and lipid peroxidation. | 2009-08-13 |
20090202582 | Water-Disposable or Water-Soluble Polymer Film as a Vehicle for Dermatologic and Cosmetic Active Agents - Described are water-dispersible or water-soluble polymer films incorporating at least one cosmetic or dermatologic active agent and a method for the production thereof. The active agents involved are particularly anti-cellulite agents, moisturizers, anti-wrinkle agents and skin smoothing agents. | 2009-08-13 |
20090202583 | Rhinovirus Vaccines - The present invention relates generally to peptide vaccines. More specifically, the present invention relates to vaccines against rhinoviruses and other related and non-related pathogenic animal viruses. In addition, the present invention relates generally to methods of designing and producing vaccines against viruses and, in certain embodiments, against rhinoviruses and other pathogenic viruses. | 2009-08-13 |
20090202584 | TREATMENT OF EPSTEIN-BARR VIRUS-ASSOCIATED DISEASES - The present invention relates to a vaccine for the treatment or prevention of an EBV-associated disease in a subject, wherein said vaccine comprises a synthetic polypeptide comprising a plurality of different segments of at least one parent EBV polypeptide, and wherein the segments are linked together in a different relationship relative to their linkage in the at least one parent EBV polypeptide. | 2009-08-13 |
20090202585 | TAT-BASED TOLEROGEN COMPOSITIONS AND METHODS FOR MAKING AND USING SAME - A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided. | 2009-08-13 |
20090202586 | ATTENUATED VACCINE FOR TULAREMIA | 2009-08-13 |
20090202587 | COMPOSITIONS COMPRISING HMW-MAA AND FRAGMENTS THEREOF, AND METHODS OF USE THEREOF - This invention provides recombinant polypeptides comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA), recombinant | 2009-08-13 |
20090202588 | Nucleic acids encoding TGEV and PRRSV sequences for improved expression of PRRSV sequences - The present invention relates to nucleic acids comprising:
| 2009-08-13 |
20090202589 | FERMENTER SYSTEM FOR BIOTECHNICAL PROCESSES - A fermenter for use in biotechnical processes in particular for culturing cells is disclosed. The object, to provide a fermenter vessel ( | 2009-08-13 |
20090202590 | INFLUENZA VACCINES EXTEMPORANEOUSLY ADSORBED TO ALUMINIUM ADJUVANTS - Antigen and adjuvant components of an adjuvanted influenza vaccine are not mixed during manufacture, but are provided as separate components for extemporaneous mixing at the time of use, for example as a kit comprising (i) an antigen component, comprising an influenza virus antigen; and (ii) an adjuvant component, comprising an aluminium salt. | 2009-08-13 |
20090202591 | LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS - Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain. | 2009-08-13 |
20090202592 | CYTOLETHAL DISTENDING TOXIN, INHIBITION AND USE THEREOF - This invention relates to immunotoxins and their use. Specifically, the invention relates to compositions comprising Cdt toxins or their inhibitors and their use in methods for treating infectious and proliferative diseases. | 2009-08-13 |
20090202593 | Novel immunogenic compositions for the prevention and treatment of meningococcal disease - The present invention relates to | 2009-08-13 |
20090202594 | Anti-bacterial Vaccine Compositions - Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines. | 2009-08-13 |
20090202595 | ANTI-PDEF ANTIBODIES AND USES THEREOF - The present invention relates to an isolated antibody or antigen-binding fragment thereof that specifically binds with high affinity to at least a portion of a segment of human prostate-derived Ets transcription factor (PDEF). The anti-PDEF antibody of the present invention is effective in prognostic and diagnostic assays for detecting PDEF with immunohistochemistry. The present invention also relates to methods of making the anti-PDEF antibody disclosed herein. The present invention further relates to vaccines against cancers associated with positive expression of PDEF, as well as methods for treating those cancers. Vectors, diagnostic kits, and hybridomas are also disclosed. | 2009-08-13 |
20090202596 | PHARMACEUTICAL COMPOSITIONS WITH BIOLOGICAL BARRIERS PERMEATION ENHANCING PROPERTIES - Pharmaceutical compositions comprising a water/oil/water (W1/O2/W3) or an oil/water/oil (O1/W2/O3) double microemulsion, with droplets size below one micron, with the drug included in the internal water phase W1 or internal oil phase 01, whereas the external oil 02 and second water phase W3 or the external water phase W2 and second oil phase 03 contain substances able to inhibit the enzymes, present in the mucosa or biological barrier to be permeated or physiological environment of administration, capable to degrade the drug or to cause its efflux from the barrier; alternatively the external oil and second water phase or external water phase and second oil phase contain permeation enhancing agents, i.e., substances able to increase the diffusion of the drug through the biological barrier. | 2009-08-13 |
20090202597 | Ache-Nmda Combination Wafer - Sheet-like pharmaceutical preparations based on hydrophilic polymers, which rapidly disintegrate upon contact with moisture and which are used to treat dementia-related illnesses The dosage form contains an active agent combination of at least two active agents which are suitable for the treatment of dementia (antidementia agents). The antidementia agents should be chosen from the group comprising acetyl cholinesterase inhibitors (AChE inhibitors) and NMDA antagonists (n-methyl-D-asparaginic acid antagonists). The use of such an active agent combination for producing an orally administrable pharmaceutical product for the treatment of dementia-related illnesses such as Alzheimer's disease, as well as a procedure for the symptomatic treatment of Alzheimer's disease by the oral administration of one of the above pharmaceutical products is also provided. | 2009-08-13 |
20090202598 | INVERT EMULSION COMPRISING AN AQUEOUS SOLUTION OF HYDROGEN PEROXIDE AND AN INERT PHASE WITH WATER SOLUBILITY OF LESS THAN 1% - The invention relates to an invert emulsion for bleaching keratin fibres and, in particular, human keratin fibres, such as hair. According to the invention, the emulsion consists of an inert phase comprising at least one non-oxygenated, non-perfluorinated liquid compound having a water solubility at 25° C. of less than 1% and an aqueous solution of hydrogen peroxide, said inert phase representing at least 20 wt.-% of the total weight of the invert emulsion and the volume-average diameter of the dispersed aqueous phase being greater than 200 nm. The invention also relates to a bleaching method which employs the inventive invert emulsion either as it is or in the form of a ready-to-use composition and to the use of said emulsion for bleaching keratin fibres. The inventive emulsion can be used to lighten keratin fibres quickly and significantly while limiting damage to said fibres and skin irritation. | 2009-08-13 |
20090202599 | SOLID ANTIPERSPIRANT COMPOSITION AND METHOD FOR MAKING SAME - Solid emulsion antiperspirant products are described. The antiperspirant products contain a continuous phase including a water-immiscible liquid and a structurant and a disperse phase including an antiperspirant active dissolved in a polar solvent. The disperse phase has a conductivity of less than or equal to about 75 mS/cm at 25° C. And the antiperspirant active has a combined peak 4 and peak 5 area percentage of at least about 25% relative to the area sum of peaks 1 to 5. Methods for making solid emulsion antiperspirant products are also described. | 2009-08-13 |
20090202600 | Oil-In-Water Emulsified Milky Skin Cosmetic Preparation - The present invention provides an oil-in-water emulsified milky skin cosmetic preparation, which is able to impart a refreshing feeling, an astringent effect, a moisturizing effect, and a softening effect to skin, when it is singly used, and which is excellent in terms of emulsion stability although it has a high water content and a low viscosity, presenting a milk white color. An oil-in-water emulsified milky skin cosmetic preparation comprising (a) a copolymer of 2-acrylamide 2-methylpropanesulfonic acid or a salt thereof/polyoxyethylene alkyl ether methacrylate, (b) an alkyl modified carboxyvinyl polymer; and (c) an alkylene oxide derivative, and having a viscosity at 25° C. of 10,000 mPa·s or less (Vismetron viscometer). It is preferable that the skin cosmetic preparation comprises 0.005% to 2.0% by mass of (a), 0.005% to 1.5% by mass of (b), and 0.005% to 15.0% by mass of (c). The skin cosmetic preparation may further comprise (d) oil havinga viscosity at 25° C. of 100 mPa·s or less and being a liquid at an ordinary temperature, arbitrarily. Furthermore, it is prefarable that the skin cosmetic preparation comprises 55% to 80% by mass of water. | 2009-08-13 |
20090202601 | METHOD FOR INHIBITING ONSET OF OR TREATING POLLEN ALLERGY - The intermolecular mutual recognition between a disease-state inducing substance (e.g., allergen group, pathogen et cetera) and a living body which functions at the time when such a disease-state inducing substance reaches the living body is inhibited by making use of pectins and nucleic acids. | 2009-08-13 |
20090202602 | PHARMACEUTICAL COMPOSITION FOR APPLICATION TO NAIL - Since treatment effects of conventional external preparations were not satisfactory, it is aimed to provide a novel external preparation that is excellent in drug permeability to nail, capable of fully exhibiting effects of an antifungal drug, and effective for treatments of diseases such as nail mycosis and nail candidiasis, particularly, treatments for nail tinea. The external preparation of this invention is a pharmaceutical composition for nail characterized by containing an antifungal drug, alkylpyrrolidone or a derivative thereof, and a crosslinking hydrogel. | 2009-08-13 |
20090202603 | Compacted 2,2-dibromo-3-nitrilopropionamide - The present invention provides an essentially pure compacted 2,2-Dibromo-3-nitrilopropionamide (DBNPA) in a granular and/or tablet and/or briquette and/or pellet form. The present invention further provides a process for preparing the same essentially pure compacted DBNPA. | 2009-08-13 |
20090202604 | Benzodiazepine Formulation in a Polyorthoester Carrier - Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of a benzodiazepine, such as midazolam, formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days. | 2009-08-13 |
20090202605 | HIGH ASPECT RATIO TEMPLATE AND METHOD FOR PRODUCING SAME FOR CENTRAL AND PERIPHERAL NERVE REPAIR - Millimeter to nano-scale structures manufactured using a multi-component polymer fiber matrix are disclosed. The use of dissimilar polymers allows the selective dissolution of the polymers at various stages of the manufacturing process. In one application, biocompatible matrixes may be formed with long pore length and small pore size. The manufacturing process begins with a first polymer fiber arranged in a matrix formed by a second polymer fiber. End caps may be attached to provide structural support and the polymer fiber matrix selectively dissolved away leaving only the long polymer fibers. These may be exposed to another product, such as a biocompatible gel to form a biocompatible matrix. The polymer fibers may then be selectively dissolved leaving only a biocompatible gel scaffold with the pores formed by the dissolved polymer fibers. The scaffolds may be used in, among other applications, the repair of central and peripheral nerves. Scaffolds for the repair of peripheral nerves may include a reservoir for the sustained release of nerve growth factor. The scaffolds may also include a multifunctional polyelectrolyte layer for the sustained release of nerve growth factor and enhance biocompatibility. | 2009-08-13 |
20090202606 | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor - The present invention relates to methods for treating or preventing cardiac conditions in a subject comprising administering to the subject two or more isoforms of hepatocyte growth factor (HGF). The present invention further relates to methods for promoting endothelial cell growth in a blood vessel comprising administering to the blood vessel two or more isoforms of hepatocyte growth factor (HGF). In one embodiment the two or more isoforms of HGF are administered as one or more polynucleotides encoding the isoforms. | 2009-08-13 |
20090202607 | HEPARIN-LIKE COMPOUNDS, THEIR PREPARATION AND USE TO PREVENT ARTERIAL THROMBOSIS ASSOCIATED WITH VASCULAR INJURY AND INTERVENTIONS - Heparin-like compounds inhibit collagen-induced platelet aggregation in flowing whole blood. The compounds share properties displayed by native mast-cell derived heparin proteoglycans (HEP-PG) and/or heparin glycosaminoglycan (HEP-GAG) molecules. The compounds are useful in prevention and treatment of severe vascular disorders including arterial thrombosis. | 2009-08-13 |
20090202608 | Devices, formulations, and methods for delivery of multiple beneficial agents - The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention. | 2009-08-13 |
20090202609 | MEDICAL DEVICE WITH COATING COMPOSITION - Coating compositions containing bioactive agents, and medical devices coated with compositions containing bioactive agents are described. In certain embodiments the coating compositions comprise a first layer, said first layer containing a bioactive agent and a polymeric material derived from poly[vinylpyrrolidone]; and a second layer outside said first layer, said second layer comprising poly(butylmethacrylate) and poly(ethylene-co-vinyl acetate). In some example embodiments the coating composition further comprises a third layer outside said first layer, said third layer comprising poly(butylmethacrylate). | 2009-08-13 |
20090202610 | Medical Implants With Polysaccharide Drug Eluting Coatings - A medical implant can include a bioerodible metal portion and a coating overlying the bioerodible metal portion. The coating can include a therapeutic agent and a polysaccharide matrix reversibly cross-linked with polyvalent metal cations. Upon implantation of the implant within a body, the therapeutic agent is released and the bioerodible metal portion erodes to release polyvalent metal cations capable of re-cross-linking the polysaccharide matrix. | 2009-08-13 |
20090202611 | COMPOSITE SELF-COHERED WEB MATERIALS - The present invention is directed to implantable bioabsorbable non-woven self-cohered web materials having a high degree of porosity. The web materials are very supple and soft, while exhibiting proportionally increased mechanical strength in one or more directions. The web materials often possess a high degree of loft. The web materials can be formed into a variety of shapes and forms suitable for use as implantable medical devices or components thereof. | 2009-08-13 |
20090202612 | Monolithic Intravaginal Rings Comprising Progesterone and Methods of Making and Uses Thereof - The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid. | 2009-08-13 |
20090202613 | Nutritionally Enhanced Therapeutic Preventative Food Supplement and Method of Making Same - The present invention is directed to a nutritionally enhanced therapeutic preventative food supplement which includes one or more food ingredients, a mineral and vitamin mix component, a base coating component, and an immune system potentiate, wherein the immune system potentiate is not denatured. The present invention includes a process to make an enhanced therapeutic food supplement and a method to potentiate the immune system of a mammal in need thereof. | 2009-08-13 |
20090202614 | METHODS FOR STEPWISE DEPOSITION OF SILK FIBROIN COATINGS - The invention provides a method for the controlled assembly of layered silk fibroin coatings using aqueous silk fibroin material. The methods described herein can be used to coat substrates of any material, shape, or size. Importantly, the described methods enable control of the biomaterial surface chemistry, thickness, morphology and structure using layered thin film coatings, or bulk coatings. Furthermore, the methods can be performed in all water and do not require intensive chemical processing enabling controlled entrapment of labile molecules such as, drugs, cytokines, and even cells or viruses to generate functional coatings that can be used in a variety of applications. | 2009-08-13 |
20090202615 | Compositions for Treating Biofilms and Methods for Using Same - Compositions containing a surface active agent and a sub-lethal amount of an antimicrobial agent and methods for using such compositions are provided herein. | 2009-08-13 |
20090202616 | Composite, Method of Producing the Composite and Uses of the Same - The invention relates to a composite comprising a semi-permeable barrier layer that is permeable to oxygen and impermeable to moisture; and a scaffold fiber layer formed by electrospinning fibers on one side of the barrier layer. | 2009-08-13 |
20090202617 | Gas based wound and tissue therapeutics - This invention provides articles of manufacture and bandages comprising compartments and layers comprising oxygen and other therapeutic gas storage forms and perfluorocarbons. This invention also provides for methods of delivering oxygen and other therapeutic gases to a tissue in a subject comprising a administering to the tissue a composition comprising a perfluorocarbon and a oxygen or therapeutic gas storage form, so as to thereby deliver oxygen or the therapeutic gas to the tissue. | 2009-08-13 |
20090202618 | Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases - The present invention is related to recombinant constructs encoding active fragments of HSP60 which are effective in treating T cell-mediated inflammatory autoimmune diseases by DNA vaccines. The HSP60 fragments of the present invention are identified by their ability to react with T cells isolated from an animal vaccinated with DNA constructs encoding HSP70 to induce Th2/3 T-cell responses. | 2009-08-13 |
20090202619 | POLYOXYALKYLENE CHAIN-CONTAINING LIPID DERIVATIVE AND LIPID FILM STRUCTURE CONTAINING SUCH DERIVATIVE - A polyoxyalkylene chain-containing lipid derivative, which is represented by the following formula (1): | 2009-08-13 |
20090202620 | POLYMER-STABILIZED LIPOSOMAL COMPOSITIONS AND METHODS OF USE - The invention provides liposomal particle compositions, which incorporate a lipophilic biodegradable polymer, such as amino acid-containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU), throughout the particles to stabilize the composition for in vivo delivery in of an incorporated biologic agent. For oral delivery, a biologic, such as insulin, is conjugated directly to the polymer. Lipids in the particle are selected to further stabilize the composition during fabrication and digestion, providing sustained delivery of the biologic with native activity. Methods of making and using the invention compositions to administer the biologic agent in vivo are also included. | 2009-08-13 |
20090202621 | CELL-SURFACE DECORATION WITH ACTIVE AGENTS - A lipid vesicle comprising a functionalized lipid comprising a tether moiety having binding affinity for a ligand portion of an active agent and the active agent are provided. Methods of decorating endothelial cells, tissues, and organs with active agents utilizing the disclosed lipid vesicles are also provided. | 2009-08-13 |
20090202622 | VIROSOME-LIKE VESICLES COMPRISING GP41-DERIVED ANTIGENS - The present invention relates to a virosome-like vesicle comprising at least a gp41-derived antigen or an analogue thereof, said gp41-derived antigen being located to the external surface of and/or encapsulated inside said vesicle and being in a convenient configuration for conferring said virosome-like vesicle with an ability to induce an immune response against a gp41 protein or a human immunodeficiency virus (HIV). | 2009-08-13 |